BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

732 related articles for article (PubMed ID: 19103995)

  • 1. Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study.
    Williams B; Lacy PS; Cruickshank JK; Collier D; Hughes AD; Stanton A; Thom S; Thurston H;
    Circulation; 2009 Jan; 119(1):53-61. PubMed ID: 19103995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
    Williams B; Lacy PS; Thom SM; Cruickshank K; Stanton A; Collier D; Hughes AD; Thurston H; O'Rourke M; ; ;
    Circulation; 2006 Mar; 113(9):1213-25. PubMed ID: 16476843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Sever PS; Poulter NR; Dahlof B; Wedel H;
    J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate.
    Williams B; Lacy PS;
    J Am Coll Cardiol; 2009 Aug; 54(8):705-13. PubMed ID: 19679248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
    Sever PS
    Am J Med; 2005 Dec; 118 Suppl 12A():3-9. PubMed ID: 16356801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia.
    Kanaki AI; Sarafidis PA; Georgianos PI; Kanavos K; Tziolas IM; Zebekakis PE; Lasaridis AN
    Am J Hypertens; 2013 May; 26(5):608-16. PubMed ID: 23449607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.
    Sever P; Dahlöf B; Poulter N; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen S; Kristinsson A; McInnes G; Mehlsen J; Nieminem M; O'Brien E; Ostergren J;
    Eur Heart J; 2006 Dec; 27(24):2982-8. PubMed ID: 17145722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.
    Sever PS; Chang CL; Gupta AK; Whitehouse A; Poulter NR;
    Eur Heart J; 2011 Oct; 32(20):2525-32. PubMed ID: 21873710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients.
    Kanbay M; Yildirir A; Bozbas H; Ulus T; Bilgi M; Muderrisoglu H; Akcay A; Ozdemir FN
    Ren Fail; 2005; 27(3):297-303. PubMed ID: 15957546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).
    Sever PS; Poulter NR; Dahlöf B; Wedel H;
    Am J Cardiol; 2005 Sep; 96(5A):39F-44F. PubMed ID: 16126022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT).
    Manisty C; Mayet J; Tapp RJ; Sever PS; Poulter N; McG Thom SA; Hughes AD;
    Hypertension; 2009 Nov; 54(5):1009-13. PubMed ID: 19720956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
    Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):29-36. PubMed ID: 15703503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study.
    Zhao SP; Peng DQ; Yu BL; Huo Y;
    Am Heart J; 2009 Oct; 158(4):509-512.e1. PubMed ID: 19781407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
    Erdine S; Ro YM; Tse HF; Howes LG; Aguilar-Salinas CA; Chaves H; Guindy R; Chopra P; Moller RA; Schou IM;
    J Hum Hypertens; 2009 Mar; 23(3):196-210. PubMed ID: 18800143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of Myocardial Ischemia Study.
    Stone PH; Lloyd-Jones DM; Kinlay S; Frei B; Carlson W; Rubenstein J; Andrews TC; Johnstone M; Sopko G; Cole H; Orav J; Selwyn AP; Creager MA;
    Circulation; 2005 Apr; 111(14):1747-55. PubMed ID: 15809368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
    Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
    J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
    Sever PS; Poulter NR; Dahlöf B; Wedel H; Collins R; Beevers G; Caulfield M; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J
    Diabetes Care; 2005 May; 28(5):1151-7. PubMed ID: 15855581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between radial and central arterial pulse wave and evaluation of central aortic pressure using the radial arterial pulse wave.
    Takazawa K; Kobayashi H; Shindo N; Tanaka N; Yamashina A
    Hypertens Res; 2007 Mar; 30(3):219-28. PubMed ID: 17510503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
    Murphy SA; Cannon CP; Wiviott SD; de Lemos JA; Blazing MA; McCabe CH; Califf RM; Braunwald E
    Am J Cardiol; 2007 Oct; 100(7):1047-51. PubMed ID: 17884359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.